A detailed history of Vanguard Group Inc transactions in Reviva Pharmaceuticals Holdings, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,025,249 shares of RVPH stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,025,249
Previous 1,025,249 -0.0%
Holding current value
$1.16 Million
Previous $1.31 Million 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.25 - $3.79 $29,266 - $88,735
23,413 Added 2.34%
1,025,249 $1.31 Million
Q1 2024

May 10, 2024

BUY
$2.76 - $5.52 $74,117 - $148,234
26,854 Added 2.75%
1,001,836 $3.79 Million
Q4 2023

Feb 14, 2024

BUY
$3.56 - $6.04 $1.28 Million - $2.17 Million
359,050 Added 58.29%
974,982 $5.02 Million
Q2 2023

Aug 14, 2023

BUY
$4.42 - $8.55 $186,356 - $360,485
42,162 Added 7.35%
615,932 $3.61 Million
Q1 2023

May 15, 2023

BUY
$3.79 - $4.87 $406,867 - $522,809
107,353 Added 23.02%
573,770 $2.4 Million
Q4 2022

Feb 10, 2023

BUY
$1.68 - $5.99 $100,838 - $359,537
60,023 Added 14.77%
466,417 $1.98 Million
Q3 2022

Nov 14, 2022

SELL
$0.14 - $2.66 $8,177 - $155,381
-58,414 Reduced 12.57%
406,394 $646,000
Q2 2022

Aug 12, 2022

SELL
$1.03 - $2.47 $721 - $1,729
-700 Reduced 0.15%
464,808 $511,000
Q1 2022

May 13, 2022

SELL
$1.61 - $3.01 $46,529 - $86,989
-28,900 Reduced 5.85%
465,508 $1.15 Million
Q4 2021

Feb 14, 2022

SELL
$2.7 - $4.23 $39,549 - $61,961
-14,648 Reduced 2.88%
494,408 $1.43 Million
Q3 2021

Nov 12, 2021

SELL
$3.29 - $4.79 $67,142 - $97,754
-20,408 Reduced 3.85%
509,056 $2.07 Million
Q2 2021

Aug 13, 2021

BUY
$4.05 - $8.7 $2.14 Million - $4.61 Million
529,464 New
529,464 $2.57 Million

Others Institutions Holding RVPH

About REVIVA PHARMACEUTICALS HOLDINGS, INC.


  • Ticker RVPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,442,900
  • Market Cap $23.1M
  • Description
  • Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...
More about RVPH
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.